<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874744</url>
  </required_header>
  <id_info>
    <org_study_id>Cerof-001</org_study_id>
    <nct_id>NCT00874744</nct_id>
  </id_info>
  <brief_title>Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>Tribeva-DME</acronym>
  <official_title>Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Goias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Goias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a single intravitreal injection of 4.0 mg of
      triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular
      edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg
      of bevacizumab regarding the ability of central macular thickness reduction. Secondary
      objectives are analysis of Visual Outcomes and variations on Intraocular Pressure. The
      patients data were statistically analyzed if there was a 24 week follow up completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between the efficacy of a single intravitreal injection of 4.0mg of triamcinolone acetonide or 1.25mg of bevacizumab in the treatment of diabetic macular edema</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare Visual Acuity between the same drug in Initial visit, 4, 12 ans 24 weeks and Visual Acuity between two group of eyes treated with different drugs.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Intraocular Pressure between the same drug in Initial visit, 4, 12 ans 24 weeks and Intraocular Pressure between two group of eyes treated with different drugs.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>1.25mg bevacizumab (0.05ml)</description>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>1.Bevacizumab</other_name>
    <other_name>2.Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone acetonide</intervention_name>
    <description>4.0 mg Triamcinolone acetonide injection</description>
    <arm_group_label>Triamcinolone</arm_group_label>
    <other_name>1. Theracort</other_name>
    <other_name>2. Kenalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic macular edema with central foveal measurement over 300 micrometers

        Exclusion Criteria:

          -  Glaucoma

          -  Vitreoretinal surgery

          -  Cataract Surgery less than 3 months prior inclusion

          -  Unilateral cataract surgery

          -  Uncontrolled Glycosylated Hemoglobin

          -  Previous Intraocular Injection

          -  Systemic Corticosteroids less than 1 month prior inclusion

          -  Macular ischemia at Fluorescein Angiography

          -  Cataract precluding fundus examination

          -  Active Proliferative Diabetic Retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David LC Isaac, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal de Goias</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>March 31, 2009</last_update_submitted>
  <last_update_submitted_qc>March 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>David Leonardo Cruvinel Isaac, MD</name_title>
    <organization>Federal University of Goi√°s</organization>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>Pharmacological treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

